Sunday, September 19, 2010

Efficacy of Daptomycin against Bacillus anthracis in a Murine Model of Anthrax Spore Inhalation{triangledown}

Daptomycin demonstrated in vitro (MIC90, 4 µg/ml) and in vivo activities against Bacillus anthracis. Twice-daily treatment with a dose of 50 mg/kg of body weight was begun 24 h after challenge and continued for 14 or 21 days; results were compared to those for controls treated with phosphate-buffered saline or ciprofloxacin. Day 43 survival rates were 6/10 mice for the 14-day and 9/10 mice for the 21-day treatment groups, compared to survival with ciprofloxacin: 8/10 and 9/10 mice, respectively. Culture results from tissues removed at the termination of the experiment were negative.

Antimicrobial Agents and Chemotherapy, October 2010, p. 4471-4473, Vol. 54, No. 10
0066-4804/10/$12.00+0     doi:10.1128/AAC.00210-10

No comments:

Post a Comment